list of fda approved glp-1 receptor agonists Oral semaglutide (Rybelsus) is the 4th agonist formulation to receive approval to reduce the risk major cardiovascular events in patients with type 2 diabetes. Our GLP-1 Agonist chart GLP-1s in the “Barbecue Belt

Diabetologia, 66 , 20072016

Are the long term effects fully known

Rosenstock J, Diamant M, Aroda VR, et al

[DOI] [PubMed] [Google Scholar] [98].Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA, Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, Journal of diabetes and its complications, 28 (2014) 393398

In fact, the GLP-1 RAs can be categorised structurally into two major groups (see Table 1

1,2 Improved glycaemic control in people with type 2 diabetes aims to prevent complications such as stroke, acute myocardial infarction, heart failure, amputation, end-stage kidney disease and blindness